ADCT-402-105-LOTIS-7
Phase I
OPEN TO ACCRUAL
A Phase 1b Open-Label Study to Evaluate the Safety and Anti-Cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-Cancer Agents in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
CARNABIOSCIENCES-C1763102
Phase I
OPEN TO ACCRUAL
A Phase 1b Study of Oral AS-1763 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non Hodgkin Lymphoma
IIT-SHAH-ELDERLY-DLBCL
Phase II
OPEN TO ACCRUAL
Multicenter Phase II Study of Mosunetuzumab and Polatuzumab Vedotin with Split-Dose CHP Chemotherapy for Elderly Patients with Diffuse Large B-Cell Lymphoma
NURIX-NX-5948-301
Phase I
OPEN TO ACCRUAL
A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies
SCHRODINGER-SGR-1505-101
Phase I
OPEN TO ACCRUAL
A Phase 1, Open-Label, Multicenter, Dose Escalation Study of SGR-1505 as Monotherapy in Patients with Mature B-Cell Malignancies
SWOG-S2114
Phase II
OPEN TO ACCRUAL
A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-Cell Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Grade IIIB Follicular Lymphoma